Results 91 to 100 of about 89,572 (287)

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region

, 2012
Oncolytic adenoviruses have shown promising efficacy in clinical trials targeting prostate cancers that frequently develop resistance to all current therapies.
Halldén Gunnel, Miranda, Enrique, Maya Pineda, Hector, Oeberg, D, Cherubini Gioia, Zita Garate (130698), Maya Pineda Hector, Gunnel Halldén, Lemoine Nick R., Öberg, Daniel,, Nick R. Lemoine (130704), Lemoine, NR, Maya Pineda, H, Gunnel Halldén (130708), Nick R Lemoine, Gioia Cherubini, Daniel Öberg (130690), Halldén, G, Miranda Enrique, Garate Zita, Hector Maya Pineda, Öberg Daniel, Garate, Zita, Garate, Z, Zita Garate, Enrique Miranda (130684), Pineda, HM, Daniel Öberg, Halldén, Gunnel, Enrique Miranda, Öberg, D, Lemoine, Nick R, Hector Maya Pineda (130688), Cherubini, Gioia, Gioia Cherubini (130694), Miranda, E, Cherubini, G   +36 more
core   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer

Frontiers in Pharmacology
Background: Docetaxel remains the standard treatment for metastatic castration-resistant prostate cancer (mCRPC). However, resistance frequently emerges as a result of hyperactivation of the PI3K/AKT and the MEK/ERK pathways. Therefore, the inhibition of
Vicenç Ruiz de Porras, Vicenç Ruiz de Porras, Vicenç Ruiz de Porras, Adrià Bernat-Peguera, Adrià Bernat-Peguera, Clara Alcon, Fernando Laguia, Maria Fernández-Saorin, Maria Fernández-Saorin, Natalia Jiménez, Ana Senan-Salinas, Ana Senan-Salinas, Carme Solé-Blanch, Carme Solé-Blanch, Andrea Feu, Mercedes Marín-Aguilera, Juan Carlos Pardo, Juan Carlos Pardo, Juan Carlos Pardo, Maria Ochoa-de-Olza, Maria Ochoa-de-Olza, Maria Ochoa-de-Olza, Joan Montero, Begoña Mellado, Begoña Mellado, Albert Font, Albert Font, Albert Font   +27 more
doaj   +1 more source

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

International Journal of Cancer, EarlyView.
Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning   +17 more
wiley   +1 more source

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

, 2014
Maria Y Ho, John R MackeyDivision of Medical Oncology, Cross Cancer Institute, Edmonton, AB, CanadaAbstract: The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic ...
Mackey JR, Ho MY
core  

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. [PDF]

, 2008
BACKGROUND: Docetaxel is more effective than doxorubicin for patients with advanced breast cancer. The Breast International Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant chemotherapy and ...
Francis, Prudence, Gelber, Richard D., Gutiérrez, Jorge, Piccart-Gebhart, Martine, Buyse, Marc, Dolci, S., Bendahmane, B., Jakesz, R., Lang, I., Di, Leo A., Gelber, R D, Gelber, R.D., Nordenskjöld, B, Nordenskjöld, Bo,, Di Leo, Angelo, Vorobiof, Daniel, Castiglione-Gertsch, Monica, Andersson, M, Crown, J., Andersson, M., Nordenskjold, B., Goldhirsch, A., Jamin, Sophie, Balil, A., Goldhirsch, Aron, BIG 02-98 Collaborative Group, Castiglione-Gertsch, M., van Hazel, Guy, Balil, Ana, Andersson, Michael, Crown, John, Vorobiof, D., Buyse, M., Nordenskjöld, Bo, Francis, P., Lang, Istvan, Gutierrez, J, Dolci, Stella, Piccart-Gebhart, M., van, Hazel G., Francis, P, Balil, A, Bendahmane, Belguendouz, Gutierrez, J., Jakesz, Raimund, Jamin, S.   +45 more
core   +1 more source

Limb Compression Therapy and Chemotherapy‐Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self‐Controlled Study(NEURO‐GLOVE Trial)

International Journal of Cancer, EarlyView.
With no effective drug‐based prevention strategies available for chemotherapy‐induced peripheral neuropathy (CIPN), research in neuroprotective approaches has grown. Of particular interest is mechanical compression, which may protect nerves by temporarily reducing blood flow during treatment. The authors here conducted a prospective trial in women with
Kadriye Başkurt, Galip Can Uyar, Enes Yeşilbaş, Fatma Zehra Altunç, Damla Erimhan Çevik, İsmet Murat Melek, Yasemin Eren, Ömür Berna Çakmak Öksüzoğlu, Kadriye Bir Yücel, Antonio Di Meglio, Isabelle Ray‐Coquard, Osman Sütcüoğlu   +11 more
wiley   +1 more source

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials

Clinical Pharmacology: Advances and Applications, 2021
Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066,
Vermunt M, Marchetti S, Beijnen J
doaj  

Docetaxel-associated myalgia–arthralgia syndrome in patients with breast cancer

, 2017
Chelsea Seguin,1 Natalie Kovacevich,1 Ioannis A Voutsadakis,2,3 1Clinical Trials Unit, 2Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Ste.
Seguin C, Voutsadakis IA, Kovacevich N
core